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Bromodomains are epigenetic readers that are re-
cruited to acetyllysine residues in histone tails.
Recent studies have identified non-acetyl acyllysine
modifications, raising the possibility that these might
be read by bromodomains. Profiling the nearly com-
plete human bromodomain family revealed that while
most human bromodomains bind only the shorter
acetyl and propionyl marks, the bromodomains of
BRD9, CECR2, and the second bromodomain of
TAF1 also recognize the longer butyryl mark. In addi-
tion, the TAF1 second bromodomain is capable of
binding crotonyl marks. None of the human bromo-
domains tested binds succinyl marks. We character-
ized structurally and biochemically the binding to
different acyl groups, identifying bromodomain resi-
dues and structural attributes that contribute to
specificity. These studies demonstrate a surprising
degree of plasticity in some human bromodomains
but no single factor controlling specificity across
the family. The identification of candidate butyryl-
and crotonyllysine readers supports the idea that
these marks could have specific physiological
functions.
INTRODUCTION
Among the many post-translational modifications on histone
tails, lysine acetylation is highly abundant and produces pro-
found biological effects (Choudhary et al., 2009; Kouzarides,
2000; Norris et al., 2009). Neutralization of the charge of the
N6-amino group is believed to disrupt the interaction between
histones and DNA, which in turn changes nucleosome dy-
namics and DNA accessibility and, ultimately, gene expression
(Kouzarides, 2007). Lysine acetylation also recruits chromatin
remodeling proteins and transcription factors through a small
acetyllysine-binding module called the bromodomain (Haynes
et al., 1992; Dhalluin et al., 1999; Owen et al., 2000). AbnormalStructure 23, 1801–protein acetylation may deregulate transcription in cancer and
other diseases, prompting efforts to discover small-molecule in-
hibitors targeting enzymes that add or remove the acetyl group,
namely the histone acetyltransferases (HATs) and histone de-
acetylases (HDACs), respectively (Furdas et al., 2012; Lane
and Chabner, 2009; Shahbazian and Grunstein, 2007). Likewise,
bromodomain-containing proteins have been implicated in dis-
ease, prompting interest in bromodomain modulation by small
molecules (Chung, 2012; Filippakopoulos and Knapp, 2014;
Hewings et al., 2012; Sanchez et al., 2014).
The activated acetyl group transferred to lysine by HATs is
carried by acetyl coenzyme A (acetyl-CoA). Acetyl-CoA is
required for biosynthesis of many biomolecules and is a feed-
stock for the citric acid cycle. Acetyl-CoA is also a central
intermediate in metabolism and is produced by pathways that
process fatty acids, sugars, and amino acids. The latter
pathways proceed, in part, through conversion of a series of
short-chain acyl-CoA intermediates, eventually leading to
acetyl-CoA or important intermediates, such as succinyl-CoA.
Each of these activated CoA intermediates is, in principle, an
acyl donor to lysine.
Intriguingly, it has been found through sensitive mass spec-
trometrymethods that a number of non-acetyl acylmodifications
are present on histone lysine residues (Arnaudo and Garcia,
2013; Olsen, 2014). The current catalog of these alternative
lysine acylations includes formylation (Jiang et al., 2007; Wis-
niewski et al., 2008), propionylation (Chen et al., 2007; Liu
et al., 2009; Tweedie-Cullen et al., 2012; Zhang et al., 2009), bu-
tyrylation (Chen et al., 2007; Tweedie-Cullen et al., 2012; Zhang
et al., 2009), crotonylation (Tan et al., 2011; Tweedie-Cullen
et al., 2012), 2-hydroxyisobutyrylation (Dai et al., 2014), succiny-
lation (Weinert et al., 2013; Xie et al., 2012), malonylation (Xie
et al., 2012), and glutarylation (Tan et al., 2014) (Figure 1A). It is
not presently understood whether thesemodifications have spe-
cific physiological functions. One possibility is that they may
instead represent a form of metabolic noise: this could result
either from non-selective introduction by HATs or from chemical
reactivity of acyl-CoA (Wagner and Payne, 2013; Weinert et al.,
2013). On the other hand, it has been reported recently that the
HAT p300 can introduce crotonyl histone modifications and
that these support transcriptional activation in a manner similar
to acetyl modifications (Sabari et al., 2015).1814, October 6, 2015 ª2015 Elsevier Ltd All rights reserved 1801
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Figure 1. Acyl Marks and Bromodomains
(A) Chemical structures of histone acyllysine modi-
fications. The colored ovals highlight the acyl group.
Lysine modifications and abbreviations are: acetyl
(Kac), formyl (Kfo), propionyl (Kpr), butyryl (Kbu),
crotonyl (Kcr), glutaryl (Kglu), succinyl (Ksu), malonyl
(Kmal), and hydroxyisobutyryl (Khib). Those indi-
cated in bold type were evaluated in the studies re-
ported here, and those shown in colors other than
blue bound to at least one human bromodomain. The
color scheme for Kac, Kpr, Kbu, and Kcr is main-
tained in figures throughout. See also Figure S1.
(B) Cartoon representation of a bromodomain (here,
that of BRD9) showing secondary structural ele-
ments and other features. The long ZA loop is shown
in blue. The critical asparagine ‘‘anchor’’ residue
(N; cyan) hydrogen bonds to bound acetyllysine
(peptide shown in green). An important specificity-
determining residue is the ‘‘gatekeeper’’ (GK)
(brown; see text and partial sequence alignment of
Figure 5A).
(C) Detailed view of the BRD4(1) binding site (PDB:
3UVW; Filippakopoulos et al., 2012) focusing on
conserved water networks. The color scheme is
taken from (B), but the orientation is different; a
portion of the ZA loop (residues 88–95) has been
omitted to aid in viewing the ligand pocket. In addi-
tion to the gatekeeper (I146) and the anchor (N140),
the nearly invariant Y97 and N135 and ‘‘WPF shelf’’ residues W81, P82, and F83 are shown. Several structurally well-defined water molecules are depicted as
small numbered spheres. We adopt the water numbering of a recent review (Hewings et al., 2012) for waters 1–4 and include ‘‘water 0’’ (shown in red) and
‘‘water1’’ (shown in pink) among structurally important and conserved waters. Water 0 is not immediately adjacent to Kac ligand, nor is it generally discussed in
published papers. Nevertheless, it appears to be among five conserved (but not explicitly defined) binding-site waters considered important in a recent
computational study (Vidler et al., 2012). Water 0 is the center of a dense network of interactions (pink dotted lines) and bridges residues Y97 and N135, linking
them either to water 2 (as in BRD9 structures, see Figure 3A) or water 3 (here). Water 1 bridges water 0 and the amide of V87. Water 1 is not ubiquitous in
bromodomain structures but it is very commonly seen and, although not depicted in some of the subsequent figures, it is present in the structures reported here.
The light-blue spheres (with interactions shown in light blue) correspond to the four canonical waters (1–4) most commonly discussed; water 1 bridges the Kac
carbonyl oxygen to Y97. Dark-blue spheres (interactions indicated in yellow) correspond to additional ‘‘ZA channel’’ waters (Hewings et al., 2012), and are shown
here to differentiate from the location and network of water 0. The center of the three ZA channel waters shown (that interacting with the side chain of Q85) has
been proposed as ‘‘the fifth conserved water molecule’’ and numbered as either water 5 or water 6 in accompanying figures (Hewings et al., 2012).The case for function, even if deleterious, of non-acetyl acyl
marks is strengthened by reports that a subset of the sirtuin-
family HDACs preferentially removes either acidic acyl modifica-
tions (malonyl [Du et al., 2011], succinyl [Du et al., 2011; Park
et al., 2013], glutaryl [Tan et al., 2014]; SIRT5) or long-chain fatty
acyl modifications (SIRT6 [Feldman et al., 2013; Jiang et al.,
2013]). In addition, short-chain fatty acyl modifications (pro-
pionyl, butyryl, crotonyl) can be removed by various sirtuins
(Bao et al., 2014; Feldman et al., 2013; Garrity et al., 2007; Smith
and Denu, 2007). Thus, these may be regulated (or regulatory)
processes, further suggesting that these acyl marks should be
‘‘read’’ in some way by chromatin-associated proteins. A strong
candidate for such an acyllysine reader is the bromodomain, but
an initial evaluation of the BET-class bromodomains of BRD2
and BRD4 suggested that the potential for reading acyl groups
larger than acetyl might be very limited (Vollmuth and Geyer,
2010).
Here, we report a broad survey of the capacity of human bro-
modomains to recognize non-acetyl acyllysine modifications.
We find that only three bromodomains (and presumably two
additional bromodomains of high sequence identity) bind to
butyryllysine (Kbu) with high affinity. Intriguingly, two of these
Kbu-binding bromodomains, those of BRD9 and CECR2,
discriminate butyryllysine from crotonyllysine, and we explore1802 Structure 23, 1801–1814, October 6, 2015 ª2015 Elsevier Ltd Athe underlying mechanism through structures of BRD9 in com-
plex with different acyllysine analogs. We find only the second
bromodomain of TAF1 to be capable of high-affinity recognition
of crotonyllysine (Kcr) and Kbu. The structure of the TAF1-Kcr
complex reveals that the crotonyl group displaces two
conserved, ordered water molecules present in the binding
pocket, resulting in a rearranged water network. Finally, we iden-
tify residues required for butyryllysine recognition by the BRD9
and CECR2 bromodomains, and engineer this capacity into
the BRD1 bromodomain.
RESULTS
Screening Human Bromodomains for Recognition of
Acetyllysine and Other Acyllysine Marks
Peptide arrays have proved to be a powerful approach to identify
specificities of epigenetic reader modules. A broad survey of hu-
man bromodomains on arrays revealed limited site specificity for
acetyllysine recognition in histone peptides, some sensitivity to
adjacent non-acetyl marks, and enhanced binding of BET-class
bromodomains to multiply acetylated peptides (Filippakopoulos
et al., 2012). To build on this work, we synthesized arrays
focusing on acylation of N-terminal tail regions of histones H3
and H4 (residues 1–40 and 1–24, respectively). These arraysll rights reserved
included peptides of different length and, for each length, all sin-
gle acetyllysine modifications and various combinations of
multiple acetylations. Because binding to peptide arrays is a
qualitative screen, we included site redundancy and context
variation in the design to give greater confidence in recognition
of a given acetyl mark, and to allow for different sequence spec-
ificities that might exist; this process resulted in a base set of 96
peptides (Table S1). Finally, we synthesized this base set of pep-
tides with non-acetyl acyl modifications (Figure 1A) to probe the
capacity of bromodomains to recognize them and for direct
comparison to recognition of acetyllysine in the same peptide
sequence. We screened a panel of 49 soluble human bromodo-
mains (of the 61 in human; Table S2), representing all structural
subfamilies.
As was observed earlier (Filippakopoulos et al., 2012), the ma-
jority of human bromodomains (including 35 of 49 screened here)
bind peptides in an acetylation-dependent manner (Table S2). All
bromodomains that we found capable of acetyllysine recognition
also bind to propionyllysine peptides on the array (see Figure S1
for examples). This suggests that the earlier finding of BRD2 and
BRD4 bromodomain recognition of propionyllysine (Vollmuth
and Geyer, 2010) reflects a general capability of the family to
bind modifications one carbon longer than acetyl.
Themajor exception to acetyl- and propionyllysine recognition
is among the group of ‘‘non-canonical’’ bromodomains (10 of 49
screened here): these lack the highly conserved asparagine ‘‘an-
chor’’ residue that forms the major hydrogen bonding interaction
with the acetyl carbonyl group (Figure 1B). Many non-canonical
bromodomains have a tyrosine residue in the equivalent posi-
tion, and in examples with reported crystal structures this substi-
tution largely blocks the binding site (ASH1L, PBRM1(1), and
SP100; Filippakopoulos et al., 2012) or favors a different binding
site and histone mark (ZMYND11; Wen et al., 2014). Not surpris-
ingly, this group of bromodomains was incapable of acetylation-
dependent peptide binding. However, we found that the non-ca-
nonical second bromodomain of PHIP (abbreviated PHIP(2) and
in an analogous manner hereafter for other multi-bromodomain
proteins), bearing a threonine anchor, does bind to acetylated
peptides and discriminates between lysine and acetyllysine pep-
tides (Figure S1). This is consistent with the reported structure of
this bromodomain bound to N-methylpyrrolidinone, an acetylly-
sine mimetic, and largely consistent with the accompanying
peptide array profiling (Filippakopoulos et al., 2012). Intriguingly,
it appears that PHIP(2) is capable of binding to formyllysine pep-
tides (Figure S1 and Table S2), an observation unique to this
bromodomain.
A Subset of Aromatic Gatekeeper Bromodomains
Recognizes Butyryllysine
BRD2 and BRD4 bromodomains have very low affinity for butyr-
yllysine (Kbu) peptides (Vollmuth and Geyer, 2010). However, we
suspected that this might not be the case for all bromodomains.
The asparagine anchor residue and structural water molecules
present in the bottom of the BRD4(1) binding pocket (Figure 1C)
are common features across the canonical bromodomain family.
(The water molecules are of particular interest—see below; how-
ever, there are inconsistencies and/or lack of adequate defini-
tions for the waters when comparing different publications. We
therefore propose an extension of the most complete annotationStructure 23, 1801–[Hewings et al., 2012] in Figure 1C.) Additional features of the
binding site include the long and variable loop connecting the
first (aZ) and second (aA) helices (ZA loop) and the short loop con-
necting the third (aB) and fourth (aC) helices (BC loop) (Figure 1B).
Flanking the BC loop is the anchor residue (end of aB) and a res-
idue commonly known as the gatekeeper (Chung et al., 2011) at
the beginning of aC (Figure 1B). The gatekeeper is generally hy-
drophobic (Filippakopoulos et al., 2012) and interacts with both
the aliphatic portion of the acetyllysine side chain and the acetyl
group itself, forming one wall of the binding pocket. In most ca-
nonical bromodomains, including those from BRD2 and BRD4,
the gatekeeper is b-branched (isoleucine or valine), and this
branching appears to restrict the size of the deepest portion of
the pocket, near where the acetyl group binds (Figure 1C). We
were particularly interested in the remaining canonical bromodo-
mains, those with leucine, phenylalanine, or tyrosine gate-
keepers (Table S2; see also Figure 5A), as it seemed that their
slightly larger binding pockets might accommodate a broader
range of acyl modifications.
Array screening revealed that a subset of the bromodomains
having tyrosine gatekeepers, those of CECR2 and BRD9 (Fig-
ure 2A) (and also TAF1(2); see below) appeared to bind strongly
to butyrylated peptides. In contrast, CECR2 and BRD9
bromodomains appeared incapable of binding to crotonylated
peptides (Figure 2A). Like the butyryl group, the crotonyl modifi-
cation consists of a linear arrangement of four carbons and dif-
fers only in the presence of a double bond (Figure 1A). It is
remarkable that CECR2 and BRD9 can apparently discriminate
between these two highly similar acyl modifications; antibodies
capable of discriminating these marks are not currently available
(Gattner et al., 2013).
To validate binding to Kbu-containing peptides, we measured
affinities for a representative peptide series (histone H4, residues
1–11 with different K5/K8 diacyl modifications; see Experimental
Procedures) by isothermal titration calorimetry (ITC) (Figure 2B).
These data indicate that BRD9 and CECR2 each bind the doubly
modified Kac, Kpr, or Kbu peptide with similar affinities and stoi-
chiometry (two bromodomains per peptide; one bromodomain
per acyllysine), while, as reported previously (Vollmuth and
Geyer, 2010), BRD4(2) binds only to Kac and Kpr peptides. In
accord with results from the array screening, we detected no sig-
nificant binding to the analogous Kcr peptide by ITC at the pro-
tein and ligand concentrations accessible. Taken together, the
data indicate that both CECR2 and BRD9 recognize the Kbu
modification and that they select against Kcr.
Structures of BRD9 Peptide Complexes Reveal a
Flexible Ligand Pocket that Allows High-Affinity Binding
of Butyryllysine
To gain insight into recognition of Kbu and discrimination against
Kcr ligands by the BRD9 bromodomain, we solved co-crystal
structures with diacyl-modified peptides, as well as a complex
with DMSO (Table 1). BRD9 structures in complex are highly
similar to the published structure of the unliganded domain (Fil-
ippakopoulos et al., 2012). In contrast to some BRD4(1) (Filippa-
kopoulos et al., 2012) and BRDT(1) (Morinie`re et al., 2009)
peptide complexes that show both a primary and secondary
Kac in a single binding pocket (and consistent with the stoichi-
ometry observed by ITC), BRD9 binds with each of the two1814, October 6, 2015 ª2015 Elsevier Ltd All rights reserved 1803
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Figure 2. BRD9 and CECR2 Recognize Butyryllysine
(A) Binding of bromodomains to peptide arrays. Arrays include a series of 96 histone H3 and histone H4 peptides, eachwith one of fourmodification types, and are
spotted in duplicate on left and right sides of the slide as indicated in the cartoon at right. See Table S1 for peptide sequences and a plate map. As previously
reported (Vollmuth and Geyer, 2010), BRD4(2) is capable of binding to Kpr but does not recognize Kbu appreciably. In contrast, BRD9 and CECR2 are broadly
capable of Kbu recognition (showing the same pattern as seen for the Kac peptides) but do not bind to Kcr.
(B) Solution binding constants and binding stoichiometry (N; peptide-to-bromodomain ratio) determined by isothermal titration calorimetry (ITC). A representative
peptide, histone H4 residues 1–11, bearing two acetyl, two propionyl, or two butyryl modifications, was assessed for binding to the three bromodomains
evaluated in (A). Note that BRD4(2) binds to only one acetyl group of the diacetylated H4 1–11 peptide per bromodomain-binding site, in contrast to the highly
(legend continued on next page)
1804 Structure 23, 1801–1814, October 6, 2015 ª2015 Elsevier Ltd All rights reserved
modified peptide lysines occupying the primary binding site of a
different bromodomain (Figure S2A). The inability to accommo-
date a second acetyl group in the binding site of BRD9 is consis-
tent with the presence of a tyrosine gatekeeper: this feature has
been associated with a ‘‘keyhole’’-type pocket (Morinie`re et al.,
2009) that can admit only a single acetyl group (Figure S2B).
Thus, we obtained two views of the binding mode for each acyl-
ated peptide (BRD9 bound to either the K5acyl or K8acyl modi-
fication). In addition, we crystallized 1:1 complexes of BRD9
bound to each of the two sites of the Kbr and Kcr peptides
(see Table 1). These structures show binding modes fully consis-
tent with those seen in 2:1 complexes. The peptide tracks
somewhat differently across the binding site in each K5/K8 com-
parison, but, importantly, the modified lysine side chains overlay
closely (Figure S2C). Thus, for simplicity, further discussion cen-
ters on K5 acyl recognition unless otherwise noted.
As in the low-affinity H3K14bu-BRD4(1) complex (Vollmuth
and Geyer, 2010), the conserved waters in the bottom of the
pocket are well defined in the BRD9 Kbu complexes, and none
is dislodged by ligand (Figure 3A). Despite this similarity, there
are differences between the BRD9 and BRD4(1) Kbu complex
structures that appear consistent with a higher-affinity interac-
tion with the former bromodomain. Butyryllysine adopts a
conformation in the BRD9-binding site that is well defined (Fig-
ure S4) but very different from that seen previously in the com-
plex with BRD4(1) (Figure S3A). In the case of BRD4(1), the car-
bon chain of the butyryl group curls up from the bottom of the
pocket, adopting a strained, eclipsed conformation with the ter-
minal methyl group pointing toward the amide NH (Figures S3A
and S3B). In contrast, the butyryl group in the BRD9 complex
adopts a more favorable staggered conformation, and the bu-
tyryl group extends more fully into the binding pocket (Figures
S3A, S3B, and S4). Overlay of the structures of BRD4(1) bound
to Kac (Vollmuth et al., 2009) or Kbu (Vollmuth and Geyer,
2010) shows that the Kbu peptide is shifted slightly outward,
and this results in repositioning of the butyryl carbonyl group
relative to the asparagine anchor (Figure 3B). This carbonyl posi-
tion may be less favorable, and, in combination with the associ-
ated strain evident in the ligand conformation, may account for
the relatively poor affinities of BRD2 and BRD4 bromodomains
for butyrylated peptides (Vollmuth and Geyer, 2010) (see also
Figure 2B). In contrast, the Kbu modification is fully accommo-
dated in the BRD9-binding site, and the butyryl carbonyl adopts
a position very similar to that seen for a bound acetyl group (Fig-
ure 3C). It appears, therefore, that the BRD9-binding pocket may
have greater flexibility than is typical.
Comparison of BRD9 structures with increasing size of acyl
modification reveals how the binding site may adjust to the larger
Kbu ligand. The bottom of the pocket is defined by the invariant
phenylalanine residue of the ‘‘WPF shelf’’ motif (F45 in BRD9; see
also Figure 1C). In the DMSO complex structure, the F45 side
chain adopts a position pointing outward toward ligand. As the
size of the acyl modification increases, the phenyl ring of F45similar BRD4(1) that accommodates two acetyl groups (Filippakopoulos et al., 20
quantifying acyl recognition capacity in the primary site. Injection series for acety
constants are shown in the table below, with average values and SEM based on
bromodomain is highly similar to that of BRD9 and appeared to bind to Kbu in a ma
confirmation of binding by ITC. See also Figure S2.
Structure 23, 1801–is deflected backward into the protein core to accommodate
ligand (Figure 3D). Interestingly, no such movement of the anal-
ogous F83 is seen in comparison of apo (Lucas et al., 2013), Kac
(Vollmuth et al., 2009), Kpr (Vollmuth and Geyer, 2010), and Kbu
(Vollmuth and Geyer, 2010) complexes of BRD4(1) (Figure 3E),
consistent with the more stringent acyl recognition preferences
of BRD4. The mobility of BRD9 F45 reaches an apparent limit
in the Kbu complex: there is very little additional deflection
induced by bound Kcr, despite themore extended ligand confor-
mation required by the trans double bond of the crotonyl group.
Instead it appears that, to fit in the pocket, the crotonyl group is
distorted from an optimal coplanar arrangement of the double
bond and amide (Figures 3F, S3C, and S4). This limit to the
size of the pocket may underlie the very low affinity of BRD9
for Kcr ligands, and provides a subtlemeans bywhich the butyryl
and crotonyl modifications may be discriminated.
The Second Bromodomain of TAF1 Recognizes
Crotonyllysine
In addition to BRD9 and CECR2 bromodomains, TAF1(2) scored
as binding to butyryllysine modifications on arrays (Figure S1;
Table S2). However, unlike BRD9 and CECR2, TAF1(2) and the
very closely similar TAF1L(2) bound robustly to crotonyllysine
peptides on arrays (Figure S1 and Table S2) and were the only
bromodomains we screened to do so. To verify this, we quanti-
fied acyl peptide binding to TAF1(2) by ITC (Figure 4A). The Kcr
peptide bound to TAF1(2) with high affinity. However, large shifts
in thermodynamic parameters were observed for Kcr binding to
TAF1(2) compared with other ligands (Table S3). In particular, the
relatively small enthalpy change observed upon binding Kcr was
augmented by a significant and favorable entropic contribution.
As it was not evident why TAF1(2) should be capable of both
Kbu and Kcr recognition, we determined structures of this bro-
modomain in 2:1 complexes (same stoichiometry as the 2:1
BRD9 structures, see Figure S2A) with each peptide (Table 1),
allowing two independent views of the modes of Kbu and Kcr
binding (Figure S5A). Bound Kbu (Figure 4B) adopts a conforma-
tion very similar to that seen in the BRD9 complex structure
(Figure 3A), with the butyryl group oriented toward the invariant
phenylalanine (F1528). However, Kcr bound to TAF1(2) adopts
a different and consistent (Figures 4C, 4D, andS5A) orientation in
the pocket. The crotonyl group displaces two of the conserved,
ordered water molecules from their usual positions (waters 3
and 4 as conventionally numbered; Hewings et al., 2012) (Fig-
ure 1C) and produces a significantly altered network of five rather
than six waters (Figures 4C, 4D, and S5). Entry into the water
pocket allows the crotonyl double bond to adopt a conformation
more nearly coplanar with the Kcr amide than that seen in the
BRD9 complex (dihedral angles defined by Nε and C1, C2, and
C3 of the acyl chain of +166 versus 120 for TAF1(2) and
BRD9 complexes, respectively; Figure S5B). The improved ge-
ometry of the Kcr group in the TAF1(2) complex is consistent
with the observed higher-affinity interaction. Furthermore, the12; Morinie`re et al., 2009); see Figure S2B. BRD4(2) is therefore better suited to
l and butyryl peptides are shown at top and center, respectively. Fitted binding
at least three experiments per entry (see also Table S3). Note that the BRD7
nner similar to BRD9 (Table S2); however, the low solubility of BRD7 precluded
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Table 1. Crystallization Conditions and Data Collection and Refinement Statistics for Crystal Structures
Structure BRD9-DMSO BRD9-KAc 2:1 BRD9-KBu 2:1 BRD9-KCr 2:1 BRD9-K5Bu BRD9-K8Bu BRD9-K5Cr BRD9-K8Cr TAF1(2)-Kbu 2:1 TAF1(2)- KCr 2:1
Ligand DMSO H4(1–11)
K5ac/K8ac
H4(1–11)
K5bu/K8bu
H4(1–11)
K5cr/K8cr
H4(1–11)
K5bu/K8bu
H4(1–11)
K5bu/K8bu
H4(1–11)
K5cr/K8cr
H4(1–11)
K5cr/K8cr
H4(1–11)
K5bu/K8bu
H4(1–11)
K5cr/K8cr
Accession (PDB) 4YY4 4YYI 4YYJ 4YYK 4YY6 4YYG 4YYD 4YYH 4YYM 4YYN
Data Collectiona
Space group C2221 P1 P1 P1 C2 C2221 C2221 C2 P212121 P212121
Cell dimensions
a, b, c (A˚) 35.15, 68.55,
105.18
24.75, 34.60,
129.36
24.82, 34.33,
129.07
24.84, 34.73,
129.08
127.80, 35.07,
30.16
35.12, 69.83,
104.55
35.44, 71.02,
102.37
126.15, 35.70,
65.02
58.22, 66.05,
81.02
59.01, 66.00,
80.30
a, b, g () 90.00, 90.00,
90.00
88.79, 90.00,
68.92
90.86, 90.00,
111.19
89.88, 89.81,
69.45
90.00, 92.32,
90.00
90.00, 90.00,
90.00
90.00, 90.00,
90.00
90.00, 99.01,
90.00
90.00, 90.00,
90.00
90.00, 90.00,
90.00
Resolution (A˚) 50.00–1.47
(1.52–1.47)b
50.00–1.50
(1.55–1.50)
50.00–1.85
(1.92–1.85)
50.00–1.68
(1.74–1.68)
50.00–1.45
(1.50–1.45)
50.00–2.10 50.00–1.52
(1.57–1.52)
50.00–1.74
(1.80–1.74)
50.00–1.50
(1.55–1.50)
50.00–1.85
(1.85)
Rsym 0.052 (0.354) 0.052 (0.252) 0.080 (0.379) 0.095 (0.475) 0.074 (0.289) 0.062 (0.473) 0.037 (0.601) 0.043 (0.432) 0.048 (0.820) 0.052 (0.681)
I/sI 29.09 (3.11) 15.34 (3.14) 9.34 (2.00) 10.91 (1.96) 13.02 (3.06) 14.66 (1.81) 36.22 (2.99) 21.00 (2.26) 29.19 (1.75) 25.94 (2.35)
Completeness (%) 96.5 (80.8) 95.1 (94.0) 97.4 (95.5) 96.6 (99.9) 95.1 (70.3) 95.2 (83.5) 99.5 (98.7) 99.8 (100.0) 99.3 (97.7) 99.9 (100.0)
Redundancy 5.8 (4.9) 2.3 (2.3) 2.0 (1.9) 3.7 (3.1) 3.1 (2.0) 4.3 (4.0) 5.9 (5.6) 3.6 (3.7) 6.0 (5.3) 6.1 (6.1)
Refinement
Resolution (A˚) 50.00–1.47 50.00–1.50 50.00–1.85 50.00–1.80 50.00–1.45 50.00–2.10 50.00–1.52 50.00–1.74 50.00–1.50 50.00–1.85
No. of reflections 20,147 57,601 31,200 28,170 21,583 7,156 18,944 28,245 47,895 26,139
Rwork/Rfree 0.217/0.234 0.206/0.242 0.198/0.244 0.225/0.261 0.180/0.208 0.253/0.311 0.199/0.226 0.212/0.260 0.218/0.260 0.213/0.243
No. of atoms 929 3,639 3,512 3,467 1,049 858 1,040 1,925 2,433 2,295
Protein 825 815/815/821/
821c
821/821/821/
821
821/821/821/
821
831 815 824 831/840 1,086/1,095 1,074/1,060
Ligand/ion 4 (DMSO) 40/40 (pep) 44/44 (pep) 44/44 (pep) 71 (pep) 22 (pep) 71 (pep) 26/26 (pep) 52/1 (pep/Ca) 77 (pep)
Water 100 287 140 95 147 21 145 202 199 84
B factors
Protein 24.73 19.52/20.72/
27.77/20.43d
16.45/17.11/
18.39/18.68
26.82/25.05/
24.06/25.02
13.64 29.09 21.32 24.69/25.75 21.36/25.31 27.86/29.27
Ligand/ion 33.72 (DMSO) 20.33/29.27
(pep)
28.22/30.18
(pep)
36.40/36.41
(pep)
46.06 (pep) 43.33 (pep) 49.84 (pep) 40.66/49.69
(pep)
42.79/23.18
(pep/Ca)
33.79 (pep)
Water 34.67 31.02 25.98 26.62 31.23 33.87 36.3 39.06 34.64 37.57
Root-mean-square deviations
Bond lengths (A˚) 0.032 0.028 0.019 0.028 0.026 0.016 0.023 0.022 0.022 0.02
Bond angles () 2.764 2.752 1.85 2.846 2.491 1.967 2.242 2.001 2.178 1.99
(Continued on next page)
1
8
0
6
S
tru
c
tu
re
2
3
,
1
8
0
1
–
1
8
1
4
,
O
c
to
b
e
r
6
,
2
0
1
5
ª
2
0
1
5
E
ls
e
v
ie
r
L
td
A
ll
rig
h
ts
re
s
e
rv
e
d
T
a
b
le
1
.
C
o
n
ti
n
u
e
d
S
tr
u
c
tu
re
B
R
D
9
-D
M
S
O
B
R
D
9
-K
A
c
2
:1
B
R
D
9
-K
B
u
2
:1
B
R
D
9
-K
C
r
2
:1
B
R
D
9
-K
5
B
u
B
R
D
9
-K
8
B
u
B
R
D
9
-K
5
C
r
B
R
D
9
-K
8
C
r
T
A
F
1
(2
)-
K
b
u
2
:1
T
A
F
1
(2
)-
K
C
r
2
:1
R
a
m
a
c
h
a
n
d
ra
n
e
P
re
fe
rr
e
d
9
8
(9
8
.9
9
%
)
3
9
5
(9
8
.2
6
%
)
3
9
6
(9
8
.0
2
%
)
3
7
6
(9
3
.0
7
%
)
1
0
6
(9
8
.1
5
%
)
9
7
(7
5
.9
8
%
)
1
0
6
(9
9
.0
7
%
)
2
0
3
(9
9
.0
2
%
)
2
5
8
(9
9
.2
3
%
)
2
4
7
(9
8
.4
1
%
)
A
llo
w
e
d
1
(1
.0
1
%
)
7
(1
.7
4
%
)
8
(1
.9
8
%
)
2
4
(5
.9
4
%
)
2
(1
.8
5
%
)
2
(2
.0
2
%
)
1
(0
.9
3
%
)
2
(0
.9
8
%
)
2
(0
.7
7
%
)
4
(1
.5
9
%
)
N
o
t
a
llo
w
e
d
0
(0
.0
0
%
)
0
(0
.0
0
%
)
0
(0
.0
0
%
)
4
(0
.9
9
%
)
0
(0
.0
0
%
)
0
(0
.0
0
%
)
0
(0
.0
0
%
)
0
(0
.0
0
%
)
0
(0
.0
0
%
)
0
(0
.0
0
%
)
C
ry
s
ta
lli
za
ti
o
n
0
.1
M
H
E
P
E
S
(p
H
7
.5
);
2
5
%
w
/v
P
E
G
3
3
5
0
0
.1
M
B
is
-t
ri
s
(p
H
6
.5
);
2
5
%
w
/v
P
E
G
3
3
5
0
0
.2
M
N
H
4
C
l;
2
0
%
w
/v
P
E
G
3
3
5
0
0
.1
M
M
E
S
(p
H
6
.5
);
1
5
%
w
/v
P
E
G
5
5
0
M
M
E
0
.2
M
N
a
m
a
lo
n
a
te
(p
H
4
.0
);
2
0
%
w
/v
P
E
G
3
3
5
0
0
.0
5
M
C
a
C
l 2
d
ih
y
d
ra
te
;
0
.1
M
B
is
-t
ri
s
(p
H
6
.5
);
3
0
%
v
/v
P
E
G
M
M
E
5
5
0
0
.2
M
N
a
m
a
lo
n
a
te
(p
H
7
.0
);
2
0
%
w
/v
P
E
G
3
3
5
0
0
.1
M
N
a
c
it
ra
te
(p
H
5
.5
);
0
.2
M
N
a
C
l;
2
0
%
w
/v
P
E
G
3
3
5
0
0
.2
M
C
a
C
l 2
;
2
0
w
/v
P
E
G
3
3
5
0
0
.2
M
C
a
a
c
e
ta
te
;
2
0
%
w
/v
P
E
G
3
3
5
0
a
A
s
in
g
le
c
ry
s
ta
l
w
a
s
u
s
e
d
to
c
o
lle
c
t
d
a
ta
fo
r
e
a
c
h
o
f
th
e
s
tr
u
c
tu
re
s
re
p
o
rt
e
d
h
e
re
.
b
V
a
lu
e
s
in
p
a
re
n
th
e
s
e
s
fo
r
h
ig
h
e
s
t-
re
s
o
lu
ti
o
n
s
h
e
ll.
c
W
h
e
re
m
u
lt
ip
le
c
h
a
in
s
e
x
is
t
fo
r
th
e
p
ro
te
in
/p
e
p
ti
d
e
c
o
m
p
le
x
e
s
,
th
e
a
to
m
n
u
m
b
e
rs
w
e
re
lis
te
d
fo
r
th
e
in
d
iv
id
u
a
l
p
o
ly
p
e
p
ti
d
e
c
h
a
in
s
s
e
p
a
ra
te
d
b
y
‘‘/
’’
,
w
h
e
re
‘‘p
e
p
’’
s
ta
n
d
s
fo
r
p
e
p
ti
d
e
.
d
W
h
e
re
m
u
lt
ip
le
c
h
a
in
s
e
x
is
t
fo
r
th
e
p
ro
te
in
/p
e
p
ti
d
e
c
o
m
p
le
x
e
s
,
th
e
B
fa
c
to
rs
w
e
re
lis
te
d
fo
r
th
e
in
d
iv
id
u
a
l
p
o
ly
p
e
p
ti
d
e
c
h
a
in
s
s
e
p
a
ra
te
d
b
y
‘‘/
’’
,
w
h
e
re
‘‘p
e
p
’’
s
ta
n
d
s
fo
r
p
e
p
ti
d
e
.
e
N
u
m
b
e
r
o
f
re
s
id
u
e
s
(p
e
rc
e
n
ta
g
e
).
Structure 23, 1801–net displacement of one water molecule may contribute to the
favorable entropy change upon Kcr binding (Table S3).
Defining Determinants for and Reengineering
Butyryllysine Specificity
Although some bromodomains proved capable of robust bu-
tyryl- and crotonyllysine recognition, we were surprised there
were not more examples. Our hypothesis was that bromodo-
mains with non-b-branched gatekeepers might have expanded
acyl recognition capacity, and indeed BRD7/9, CECR2, and
TAF1(2)/TAF1L(2) (of SGC structural classes IV, I, and VII,
respectively; Filippakopoulos et al., 2012), with tyrosine gate-
keepers (Figure 5A), fall into this group. However, there are other
bromodomains with aromatic gatekeepers (Figure 5A) that do
not bind appreciably to Kbu on arrays: class I bromodomains
GCN5, PCAF, and BPTF, and class IV bromodomains BRPF1,
BRD1, and BRPF3. (However, note that GCN5 and PCAF bind
poorly even to acetylated peptides on arrays [Table S2].) Taken
together, an aromatic gatekeeper is necessary for Kbu recogni-
tion but not sufficient. In examining the structures of BRD9 and
the deflecting F45 (Figure 3D), it appeared that a methionine res-
idue (M92) in the protein core behind F45 might aid in its mobility
and, along with the tyrosine gatekeeper, create a larger binding
pocket. The equivalent residue in CECR2 (position 506) is also
methionine, while in other bromodomains it is often a more rigid
b-branched residue (isoleucine in the BRPF family and valine in
GCN5/PCAF; see Figure 5A). Interestingly, in the BET-class bro-
modomains, which do not bind Kbu with high affinity (Vollmuth
and Geyer, 2010) (Figure 2B), the equivalent residue is invariably
methionine, but the BET-class bromodomains are encumbered
with a b-branched gatekeeper residue.
To explore whether the tyrosine gatekeeper and core methio-
nine were required for Kbu recognition, we mutated these resi-
dues to isoleucine in CECR2 and BRD9. Importantly, these
mutants retain full affinity for the Kac peptide (Figure 5B) and
have thermal stabilities comparable to those of the wild-type
bromodomains (Table S4). However, mutation of either residue
in BRD9 or in CECR2 resulted in the loss of any detectable bind-
ing to the Kbu peptide (Figure 5B). This suggests that restriction
of the binding pocket by a b-branched gatekeeper or a relatively
rigid protein core can each contribute to selectivity for Kac. How-
ever, the system is not entirely modular: consistent with a previ-
ous report (Morinie`re et al., 2009), substituting tyrosine for the
isoleucine gatekeeper in BET-class bromodomains did not
confer any expanded acyl recognition capacity despite the pres-
ence of the core methionine, nor did we find any case in which
introducing a core methionine in the presence of a permissive
gatekeeper (for example, into the BRPF family) resulted in a
gain of Kbu binding (not shown).
Given our inability to engineer novel Kbu binding in the initial
round of mutagenesis, we sought additional features that might
govern ligand specificity. The ‘‘WPF shelf’’ region of the ZA loop
contributes to one side of the ligand-binding pocket. In the class
IV bromodomains (Figure 5A), the canonical WPF motif is re-
placed by GFF (BRD9) or XIF (BRPF family). BRPF1 I652 appears
to restrict this side of the binding pocket compared with F44 of
BRD9 (Figure 6A, right). Accordingly, we evaluated I-to-F mu-
tants across the family (BRPF1, BRD1, BRPF3). Screening of
the mutants on peptide arrays showed a general gain in Kbu1814, October 6, 2015 ª2015 Elsevier Ltd All rights reserved 1807
B A 
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Figure 3. Acyllysine Recognition by BRD9
(A) H4K5bu (orange) bound to BRD9. The butyryl carbonyl (top) forms the
expected hydrogen bond to N100 (the anchor). Y106 is the gatekeeper residue
discussed in the text. The small numbered spheres indicate ordered waters
(see Figure 1C); these form a network of hydrogen bonds with backbone
carbonyls ofM92 (water 2), M65 (waters 3), F47 (water 4), and F44 (water 4), the
side chains of Y57 and N95, and the ligand acyl oxygen. The methionine side
chain shown in dot representation (M59) is from an adjacent BRD9monomer in
the crystal, and packs against a shallow cleft formed by side chains of F44 and
Y106 and the ligand (near Nε andC2 but not close to C3 or C4). The small white
sphere (unnumbered) is water 1 (see Figure 1C). Note that for consistency
with entry PDB: 3HME, residue numbering is that of isoform 3 (UniProt:
Q9H8M2-3) rather than that of isoform 1 (UniProt: Q9H8M2-5).
(B and C) Comparison of Kbu binding to BRD4(1) and BRD9. Kac and Kbu
complexes are overlaid. (B) For BRD4, the Kbu interaction is of very low affinity,
and the acyl group (cyan; PDB: 3MUL; Vollmuth and Geyer, 2010) is shifted in
the binding site relative to the position of Kac (green; PDB: 3JVK; Vollmuth
et al., 2009). Although not shown for clarity, the two protein structures overlay
closely and exhibit no significant side-chain rearrangements. (C) For BRD9,
Kbu ligand (orange) occupies a position similar to that of Kac ligand (green),
and overlaid proteins show no significant differences in the binding pocket
other than that shown in (D).
(D) BRD9 bound to ligands of increasing size. Structures in complex with
DMSO (gray), Kac (green), Kbu (orange), and Kcr (pink) are overlaid. With the
exception of BRD9 (cyan) in the Kbu complex, bromodomain residues are
colored to match ligand. The F45 phenyl ring deflects back into the protein
core as ligand size increases, but this appears to reach nearly its maximum
extent in the Kbu complex: there is little additional movement apparent in the
very low-affinity Kcr complex. Note that the view is clipped in front so that F45
can be seen clearly.
(E) Overlaid structures of BRD4(1) in apo form or bound to ligands of increasing
size show that F83 (analogous to BRD9 F45) does not move to accommodate
ligand. Structures (in addition to those shown in B) are apo (gray; PDB: 4LYI;
Lucas et al., 2013) and Kpr-bound (darker green; PDB: 3MUK; Vollmuth and
Geyer, 2010).
(F) Low-affinity Kcr binding to BRD9 is accommodated by structural defor-
mation of the ligand. A different view (relative to D) of bound Kbu (orange) and
Kcr (pink) shows the well-accommodated conformation of the butyryl group.
The trans double bond of the crotonyl group precludes the ligand adopting
1808 Structure 23, 1801–1814, October 6, 2015 ª2015 Elsevier Ltd Abinding (Figures 6A and S6). For wild-type and mutant BRD1, we
quantified binding by ITC (Figure 6B). Importantly, the mutation
does not impair Kac binding yet allows equally potent recogni-
tion of a new mark, Kbu. Like CECR2 and BRD9, I586F mutant
BRD1 discriminates against Kcr (Figure 6A).
DISCUSSION
Lysine acetylation is an integrator of information on metabolic
status (Gut and Verdin, 2013; Lu and Thompson, 2012; Xing
and Poirier, 2012; Zhao et al., 2010), especially in mitochondria
(Amado et al., 2014; Newman et al., 2012), circadian rhythms
(Masri et al., 2013), cellular environment (McBrian et al., 2013),
and signal transduction pathways (Bannister and Miska, 2000;
Choudhary et al., 2009; Shahbazian andGrunstein, 2007). Efforts
to catalog the ‘‘acetylome’’ have revealed that, in addition to his-
tones, many non-histone proteins are modified (Choudhary
et al., 2009; Kaluarachchi Duffy et al., 2012; Weinert et al.,
2011). Indeed, the scope and potential importance of acetylation
biology has been equated to that of phosphorylation (Kouzar-
ides, 2000; Norris et al., 2009; Smith andWorkman, 2009). Acet-
ylation status can be interpreted in a number of ways, including
regulation of enzymatic activity, direct changes in chromatin
structure, or localization of protein complexes to histones
through bromodomain proteins. Accordingly, bromodomains
and other acetyllysine readers (Li et al., 2014; Zeng et al.,
2010) are often found in proteins that function in transcriptional
regulation and chromatin remodeling. The investigation of bro-
modomains has advanced by use of selective, cell-permeable
small-molecule inhibitors (chemical probes) that compete with
acetyllysine for binding to the bromodomain, and thereby disrupt
its function within larger proteins and complexes (Chung, 2012;
Filippakopoulos and Knapp, 2014; Hewings et al., 2012; San-
chez et al., 2014). In the case of BET-class bromodomains,
such studies have revealed profound biological effects, propel-
ling BET inhibitors into clinical studies (Dawson et al., 2012; Shi
and Vakoc, 2014).
In this study, we establish that a small number of human bro-
modomains, those of TAF1, CECR2, and BRD9 (and presumably
also those of the closely related TAF1L and BRD7) are capable of
reading crotonyl or butyryl marks on histone peptides with affin-
ities comparable to their affinities for acetyl modifications. This
suggests that such binding could be physiologically meaningful
and potentially function in chromatin regulation. It is interesting
that, even for those bromodomains capable of recognizing larger
acyl groups, we found no preferential binding to these marks
over acetyl. Finally, we found that no bromodomain is capable
of recognizing succinyl modifications, and only the non-canoni-
cal bromodomain PHIP(2) appears to bind formyl modifications
in histone peptides (Figure S1). Formyllysine may be the conse-
quence of oxidative damage (Edrissi et al., 2013; Jiang et al.,
2007) rather than a regulated mark, perhaps explaining why itsuch a conformation, and instead the double bond twists out of the plane of the
amide group (see also Figure S3C). In both structures, the six ordered water
molecules described in (A) and the text (five of these shown as small spheres)
remain largely in place, although electron density is weak for select examples
(see Figure S2C).
See also Figures S2, S3, and S4.
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AB
Figure 5. Acyl Selectivity Determinants in
Bromodomains
(A) Aligned partial sequences of bromodomains
showing positions of key features. Residue
numbers correspond to the residue marked by a
dot in the top sequence of each class. Names are
shown in bold for bromodomains capable of bu-
tyryllysine recognition (*see note for BRD7 in
legend of Figure 2). Invariant or very common
features are highlighted in cyan, while more vari-
able features targeted by mutagenesis are high-
lighted in yellow, brown, or gray. The cartoon on
the right (BRD9) includes specific side chains dis-
cussed in the text labeled with circles and color
coded to BRD9 in the alignment. See Figure 1B for
additional labeling of features.
(B) Kbu recognition by BRD9 and CECR2 requires
a permissive tyrosine gatekeeper and a core
methionine residue. ITC results for wild-type and
mutant BRD9 and CECR2. Fitted values are aver-
ages and SEM from at least three ITC experiments
per entry (see also Table S3).is not recognized by canonical bromodomains or HDACs (Edrissi
et al., 2013). In contrast, succinyllysine appears to be an evolu-
tionarily conserved mark (Weinert et al., 2013; Xie et al., 2012)
with a dedicated, carboxyl-specific deacetylase, SIRT5 (Du
et al., 2011; Park et al., 2013; Peng et al., 2011; Tan et al.,
2014). It will be interesting to explore whether another class of
proteins may read succinyllysine or similar acidic modifications.Figure 4. TAF1(2) Is Competent to Read Crotonyllysine
(A) Evaluation of Kac, Kbu, and Kcr binding to TAF1(2) by ITC. Measurements were made at pH 7.0 in additio
case, the traces shown are representative of pH 7.0 data. Average values and SEMare based on threemeasur
and seven measurements for the Kcr peptide at pH 7.0 (Table S3).
(B) Kbu peptide bound to TAF1(2). The K5 modification is shown, and the binding mode appears equivalent to
conformation to that shown in Figure 3A and the presence of five ordered water molecules (the sixth, water 
the case of TAF1, water 0 appears slightly closer to water 3 (yellow dotted line) than to water 2 (as in BRD9 com
the upper left part of the image are from I1575, M1548, H1530, and P1527, shown interacting with waters 2
(C) Kcr peptide bound to TAF1(2). The orientation is the same as in (B) and shows the crotonyl group extending
in (B). Note that twowater molecules (numbers 3 and 4) have been displaced by ligand. A new, shifted network
by waters 00 and 30 (so designated because they form connections similar to waters 0 and 3; see text and D
(D) Overlay of Kcr and Kbu TAF1(2) complexes reoriented to highlight the different binding modes of the acy
networks. The color scheme is the same as in (B) and (C). H1530 is not shown for the Kcr complex so that the
complexmay be seen. The unlabeled backbone carbonyls on the right are those of I1575 andM1548, interact
respectively. As noted above, water 30 shows connectivity related to that of canonical water 3 (water 2, wat
position of water 3 in the Kbu complex and much closer to N1578. Water 00 shifts 1.2 A˚ from the position of
(E) Additional interactions of TAF1(2) with the crotonyl group. The side chain of V1532 and the carbonyls of P
interacts with water 3 or 4) point toward the crotonyl group and pack loosely. Unlike the butyryl group in the
group with F1528. The waters are omitted from this panel for clarity.
See also Figures S4 and S5.
1810 Structure 23, 1801–1814, October 6, 2015 ª2015 Elsevier Ltd All rights reservedMutagenesis of BRD9 and CECR2
identified two residues as critical in allow-
ing high-affinity recognition of butyrylly-
sine: a tyrosine gatekeeper and a core
methionine. However, while an aromatic
gatekeeper appeared to be required, it
was not sufficient to support Kbu binding,
and, in the case of TAF1(2), Kbu bound
with substantial (if not full) affinity despite
TAF1(2) lacking the core methionine resi-
due. Likewise, introduction of these resi-dues into Kac-specific bromodomains did not yield mutants
with broader recognition properties. In the case of BRD1 and
other BRPF family bromodomains, a residue substitution at a
third site (in the ‘‘WPF shelf’’ region) was instead sufficient to re-
cruit novel butyryllysine recognition. As in the case of TAF1(2),
this was possible despite the presence in the BRPF family of
the core isoleucine residue that, when introduced into BRD9 orn to pH 7.5 (see Experimental Procedures). In each
ements for Kac and Kbu peptides at each condition
that of K8bu (Figure S4A). Note similarity of ligand
1, is not shown to avoid obscuring other details). In
plexes). The four unlabeled backbone carbonyls in
, 3, 4, and 4, respectively.
further into the pocket than does the butyryl group
has formed in which the original water 0 is replaced
). The white sphere is water 1 (see Figure 1C).
l carbon chains and details of the rearranged water
interaction between water 4 and H1530 in the Kbu
ing with waters 2 and 0, 3 (or 00, 30 for Kcr complex),
er 0, H1530). However, it is located 3 A˚ from the
water 0 and further away from N1578 (see also C).
1527, H1530, and M1548 (each carbonyl normally
Kbu complex, there is little packing of the crotonyl
AB
Figure 6. Gain of Kbu Recognition in a ZA
Loop Mutant of BRD1
(A) Left: Binding of BRD1 wild-type and mutant as-
sessed by peptide array. Wild-type bromodomain
shows no appreciable recognition of Kbu peptides,
whereas significant binding is evident for the I586F
mutant. Right: Overlay of BRD9 and BRPF1 peptide
complexes (PDB: 4QYD; Lubula et al., 2014)
showing proximity of the site of mutation and bound
ligand. Key differences between BRD9 and BRPF1
are indicated in color-coded labels (these three
residues are identical in BRD1 and BRPF1; BRD1
numbering is I586, I634, and F648). Black labels
relate to features shown in Figure 5A.
(B) ITC assessment of the acyl specificity change
indicated by data shown in (A). Reported values are
averages and SEM based on three ITC experiments
per entry (Table S3).
See also Figure S6.CECR2, abolished Kbu recognition. It would seem, therefore,
that bromodomain acyl ligand recognition and specificity are
complex. Nevertheless, it appears that rather simple changes
in the bromodomain can lead to gain of new binding function,
and that the high specificity that most bromodomains show for
Kac may be under active selection.
The structures we report illustrate further both the plasticity of
the bromodomain binding site and its subtlety. High-affinity bu-
tyryllysine recognition appears to require deformation in the pro-
tein core to accommodate the acyl carbon chain in a particular
bent conformation. This conformation is not achievable by theStructure 23, 1801–1814, October 6, 2015unsaturated crotonyl group, which is there-
fore excluded. In the case of TAF1(2) an
alternative is available, namely displace-
ment of conserved waters in the base of
the pocket by a reoriented crotonyl group.
It is not presently clear why water displace-
ment is possible for TAF1(2) but not for
BRD9 (nor, presumably, CECR2). In any
case, the discrimination of butyryl and cro-
tonyl modifications by CECR2 and BRD9 is
remarkable, and suggests that these his-
tone marks could have distinct physiolog-
ical functions.
The expansion of the histone acyllysine
repertoire to include a broad range of mod-
ifications beyond acetyl is provocative and
suggests a more nuanced view of cellular
response to metabolic status at the level
of chromatin. However, these non-acetyl
modifications are considerably less abun-
dant than acetyllysine, and may be largely
restricted to particular tissues (Tan et al.,
2011) or limited to a narrower range of his-
tone lysines than the acetyl mark. Accord-
ingly, although associations have been
drawn between genomic locations of these
marks and possible functions (Dai et al.,
2014; Tan et al., 2011; Wisniewski et al.,2008; Xie et al., 2012), there is little information available about
what the specific consequences of these modifications (or their
loss) might be. One possibility is that a non-acetyl modification
could compete with acetylation at a particular site and thereby
antagonize recruitment of an acetyl-specific reader. On the other
hand, a non-acetyl modification might partially mimic the direct
effect of acetylation on chromatin structure, as it would be
capable of neutralizing positive charge on histone tails in the
same way as acetylation and thereby decompact chromatin.
An exciting possibility is that non-acetyl acyllysine marks
lead to defined changes in transcriptional status based on aª2015 Elsevier Ltd All rights reserved 1811
difference in the complexes recruited to such sites. This would
provide a new means of response to changes in the proportion
of acyl-CoAs in the cell (Newman et al., 2012), allowing fine-tun-
ing of transcriptional response tometabolic status (Eckel-Mahan
et al., 2012; Masri et al., 2012). The identification of reader do-
mains capable of interpreting non-acetyl acyl marks is a key
step in establishing the potential of this latter mechanism.
EXPERIMENTAL PROCEDURES
Bromodomain Protein Production
Bromodomains were expressed in Escherichia coli and purified by a combina-
tion of affinity and conventional chromatography methods. Details are given in
the Supplemental Experimental Procedures. Full details of the constructs used
(DNA sequence, tagging scheme, resulting expressed protein, and amino acid
boundaries within the full-length protein) are given in Table S5.
Synthesis of Peptides and Peptide Arrays
Peptides were synthesized by standard solid-phase Fmoc chemistry (Anas-
pec). Peptides for arrays were custom synthesized in 384-well format using
CelluSpots technology and spotted on slides for binding studies (Intavis Pep-
tide Services). Fmoc-acyllysines not commercially available were synthesized
as described in the Supplemental Experimental Procedures. See also Table S1
for peptide sequences.
Screening of Bromodomain Binding to Peptide Arrays
Peptide arrays were incubated with 25 mM bromodomain solution overnight at
4C. Bound bromodomain was detected through the FLAG tag (a-FLAG M2
HRP conjugate) as described in Supplemental Experimental Procedures.
See also Table S2.
Measurement of Peptide Dissociation Constants by ITC
Experiments were carried out on an ITC200 (MicroCal). Typically, 200–400 mM
protein was placed in the calorimeter cell and peptide at a 10-fold higher con-
centration (2000–4000 mM)was injected into the cell. All experiments were per-
formed at 25C (298 K) in 20 mM HEPES (pH 7.5) and 150 mM NaCl, except
those conducted at pH 7.0 as noted for TAF1(2). The enthalpy change for bind-
ing of the Kcr peptide to TAF1(2) at pH 7.5 is too close to zero to allowKD deter-
mination by this method. Observations from the protein-folding field (Becktel
and Schellman, 1987) provide a rationale for use of pH change to shift thermo-
dynamic parameters. Measured affinities for Kac and Kbu peptides shift only
2- to 4-fold with the shift in pH, and binding of TAF1(2) to arrays appears similar
at these pH values (not shown). Thermodynamic parameters were fitted in the
MicroCal Origin software package using a single-site model, and are reported
in detail in Table S3.
Crystallization and Structure Determination
Peptide complexes of BRD9 and TAF1(2) bromodomains were crystallized as
described in Supplemental Experimental Procedures (see also Table 1 for spe-
cific conditions). Complete diffraction datasets for the protein-peptide com-
plex crystals were collected either at the SER-CAT beamline at the Advanced
Photon Source or the CMCF beamline at the Canadian Light Source. The data
were processed and scaled with the HKL3000 program suite (Minor et al.,
2006). The structures were solved by molecular replacement with 3HME
(BRD9) or 1EQF (TAF1) as search models using Phaser in the CCP4 suite
(McCoy et al., 2007; Potterton et al., 2002), and were refined using REFMAC5
(Winn et al., 2003) built into the Coot program (Emsley and Cowtan, 2004).
Peptides were built onto the 2Fo-Fc and Fo-Fc maps at the final stage of the
refinement. Structures are validated using the built-in tools in Coot, as well
as with PROCHECK (Laskowski et al., 1993) and MolProbity (Chen et al.,
2010). Crystallographic data and refinement statistics of the individual struc-
tures are summarized in Table 1.
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